Nebido® publications portal (NPP)

Welcome to the Nebido® publications portal (NPP)

The purpose of the Nebido® publications portal (NPP) is to present testosterone related research, in an easily searchable and navigable interface, to health professionals who search for scientific information on hypogonadism, testosterone replacement therapy and testosterone related health issues.

MULTICENTER STUDY
 | 
2017
Rosen RC
Wu F
Behre HM
Porst H
Meuleman EJH
Maggi M
Romero-Otero J
Martinez-Salamanca JI
Jones TH
Debruyne FMJ
Kurth KH
Hackett GI
Quinton R
Stroberg P
Reisman Y
Pescatori ES
Morales A
Bassas L
Cruz N
Cunningham GR
Wheaton OA; RHYME Investigators
The results of this relatively long-term prospective, multinational hypogonadism clinical outcomes registry provide further evidence of sustained and consistent benefits of testosterone therapy in improving long-term quality of life and sexual function.
The RHYME study, unlike most other observational studies, provides data for comparison of testosterone therapy effects with outcomes for an untreated group at the same study sites. Most importantly, our data show consistent improvements across measurements, over time, and across treatment conditions in testosterone treated men compared with a similar group of patients not receiving testosterone treatment.
CLINICAL PRACTICE GUIDELINE
 | 
2017
Saad F
Röhrig G
von Haehling S
Traish A
Substantial evidence exists suggesting that testosterone treatment improves muscle mass, reduces FM, and may improve strength and physical function. Testosterone treatment brings about a significant increase in muscle strength in older men.
Even modest improvements in muscle mass and strength and gains in physical function in response to testosterone treatment may be of great importance for attenuating the progression of muscle and physical decline in older men.
OBSERVATIONAL STUDY PROSPECTIVE (EPIDEMIOLOGY)
 | 
2017
Ng Tang Fui M
Hoermann R
Zajac JD
Grossmann M
Clin Endocrinol (Oxf). 2017 Oct;87(4):336-343.
In his observational double blind and placebo-controlled follow-up study of a 56 week randomized controlled trial of testosterone treatment in dieting obese men, the benefits of testosterone on body composition were not maintained when assessed after at least 12 months of testosterone treatment cessation.
In addition, there was no evidence that previous testosterone treatment led to sustained iatrogenic suppression of the HPT axis, nor was it associated with persisting changes in haematological and prostate safety parameters.
CONTROLLED CLINICAL TRIAL
 | 
2017
Ng Tang Fui M
Hoermann R
Grossmann M
J Endocr Soc. 2017 Feb 28;1(4):302-312.
In this comprehensive evaluation of testosterone effects on circulating levels of key adipokines and gut hormones among obese men subjected to a rigorous weight loss program, it was found that testosterone treatment reduced leptin levels above and beyond the effects of diet alone.
The lower leptin levels in testosterone-treated men may reflect a lessening of leptin resistance by mechanisms other than a reduction in adiposity, as leptin levels were lower in testosterone treated men even with adjustments for the loss of fat mass. In contrast, changes in weight and fat mass during diet exerted a more dominant effect on circulating concentrations of other key modulators of energy homeostasis compared with testosterone treatment.
CONTROLLED CLINICAL TRIAL
 | 
2017
Ng Tang Fui M
Hoermann R
Prendergast LA
Zajac JD
Grossmann M
Among middle-aged obese men with lowered testosterone levels, testosterone treatment for 56 weeks improved symptoms of androgen deficiency above and beyond what was achieved with weight loss alone.
This was accompanied with greater diet-induced loss of total fat and visceral fat mass and preserved lean mass, compared to the placebo group.
OBSERVATIONAL STUDY PROSPECTIVE (EPIDEMIOLOGY)
 | 
2017
Salman M
Yassin DJ
Shoukfeh H
Nettleship JE
Yassin A
This study aimed to identify easily assessed factors that predict the likelihood of successful long-term weight loss due to TRT alone.
The results from this present study demonstrate that of the parameters measured, sustained weight loss in men with hypogonadism undergoing TRT may be more likely to be achieved by men who lose 3% of baseline body weight within the first year, men with a BMI over 30 (kg/m2), or men with a waist circumference measurement greater than 102 cm at the onset of TRT treatment
CLINICAL PRACTICE GUIDELINE
 | 
2017
Anaissie J
Roberts NH
Wang P
Yafi FA
Sex Med Rev. 2017 Apr;5(2):200-210.
The scientific literature supports a potential relation between low T and all elements of MetS; insulin resistance, dysipidemia, hypertension, cardiovascular disease and obesity.
A growing number of studies show benefits of TRT for the treatment of components of MetS. Studies show TRT reduces obesity markers (such as waist circumference) and improves dyslipidemia and glycemic control.
SURVEY
 | 
2017
Gilbert K
Cimmino CB
Beebe LC
Mehta A
Urology. 2017 May;103:27-33.
This is the first report assessing patient knowledge about testosterone deficiency and testosterone therapy, in a clinical setting. ‘Low energy’, ‘decreased libido’ and ‘weak erections’ were the most commonly reported symptoms associated with testosterone deficiency. Accordingly, the most commonly identified benefits associated with TRT were ‘feeling better’, ‘increased energy’ and ‘improved sexual function’.
The fact that individuals with a medical diagnosis of hypogonadism were no better informed of the risks and benefits of TRT than the rest of the study population, is also suggestive of inadequacies in patient counseling, and/or patient retention of information provided in the healthcare setting.
OBSERVATIONAL STUDY PROSPECTIVE (EPIDEMIOLOGY)
 | 
2017
Cheetham TC
An J
Jacobsen SJ
Niu F
Sidney S
Quesenberry CP
VanDenEeden SK
JAMA Intern Med. 2017 Apr 1;177(4):491-499.
In this study of testosterone deficient men, TRT was associated with a decreased risk of CV events. These results were consistent in analyses stratified by age, the presence or absence of baseline CV risk factors, and in a sensitivity analysis in which follow-up was restricted to the first 90, 180, or 365 days.
While these findings are in contrast from those of the two observational studies of TRT that generated media attention (Viegen 2013 and Finkle 2014), these finding are consistent with the larger body of evidence on the benefits of TRT in testosterone deficient men.
OBSERVATIONAL STUDY PROSPECTIVE (EPIDEMIOLOGY)
 | 
2017
Canguven O
Talib RA
El Ansari W
Yassin DJ
Salman M
Al-Ansari A
Andrologia. 2017 Dec;49(10).
Testosterone treatment with long-acting testosterone undecanoate for 1 year improves the components of the metabolic syndrome; results showed reduction in total cholesterol, triglycerides, HbA1c, body weight and waist circumference, and increase in HDL-C levels.
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Mon, 16/09/2019

Bayer logo